Qi-Wen Chen1, Hai-Feng Ying2, Song Gao3, Ye-Hua Shen3, Zhi-Qiang Meng3, Hao Chen3, Zhen Chen4, Wen-Jing Teng5. 1. Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China; Fudan University, Institute of Clinical Epidemiology, School of Public Health, Key Laboratory of Public Health Safety of Ministry of Education, 200032 Shanghai, PR China. 2. Shanghai Jiaotong University, School of Medicine, Ruijin Hospital, Department of Traditional Chinese Medicine, 200025 Shanghai, PR China. 3. Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China. 4. Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China. Electronic address: cz120@mail.sh.cn. 5. University of Traditional Chinese Medicine, Post Graduate School of Shandong, Weifang Hospital of Traditional Chinese Medicine, Cancer Treatment Center, First Department, 250355 Jinan, Shandong Province, PR China.
Abstract
BACKGROUND: To determine whether the use of radiofrequency ablation (RFA) plus transcatheter arterial chemoembolization (TACE) is more effective than the use of RFA alone for patients with hepatocellular carcinoma (HCC). METHODS: A computer-based search was performed. Randomised trials comparing RFA plus TACE and RFA alone for treatment of HCC were included in this meta-analysis. The outcome of interest for our analysis was survival (recurrence-free survival and overall survival). RESULTS: Eight trials with 648 patients were eligible for this meta-analysis. Our pooled results suggest that RFA plus TACE is associated with a significant advantage in recurrence-free survival (RFS) (HR=0.58; 95% CI=0.42-0.80, P=0.001), and overall survival (OS) (HR=0.60; 95% CI=0.47-0.76, P<0.001). CONCLUSION: TACE combined with RFA was more effective than RFA alone, especially for treatment for intermediate and large-size hepatic tumours or younger patients with HCC.
BACKGROUND: To determine whether the use of radiofrequency ablation (RFA) plus transcatheter arterial chemoembolization (TACE) is more effective than the use of RFA alone for patients with hepatocellular carcinoma (HCC). METHODS: A computer-based search was performed. Randomised trials comparing RFA plus TACE and RFA alone for treatment of HCC were included in this meta-analysis. The outcome of interest for our analysis was survival (recurrence-free survival and overall survival). RESULTS: Eight trials with 648 patients were eligible for this meta-analysis. Our pooled results suggest that RFA plus TACE is associated with a significant advantage in recurrence-free survival (RFS) (HR=0.58; 95% CI=0.42-0.80, P=0.001), and overall survival (OS) (HR=0.60; 95% CI=0.47-0.76, P<0.001). CONCLUSION: TACE combined with RFA was more effective than RFA alone, especially for treatment for intermediate and large-size hepatic tumours or younger patients with HCC.
Authors: Joseph D Morrison; Collin K Schlager; Amanda E Lee; Richard B van Breemen; Ron C Gaba Journal: Diagn Interv Radiol Date: 2018 Jan-Feb Impact factor: 2.630
Authors: Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis Journal: Abdom Radiol (NY) Date: 2021-04-15